Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC and Radiation in Localized Soft Tissue Sarcoma
NCT02923778Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2019
- Primary completion
- Dec 2026
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in soft tissue sarcoma (STS), sponsored by National Cancer Institute. Primary endpoints: Pathologic complete response rate up to 5 years and Incidence of post-surgical wound complications. Started Dec 2019; status: active, not recruiting.
02
Drugs
talimogene laherparepvec
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02923778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923778.